Clinical Trials · NCT05882032
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 29
- Start date
- Jun 2023
- Locations
- 4 sites, United States
- Primary endpoint
- Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of LY3502970